Animal Imaging Center, Institute for Biomedical Engineering, ETH, Wolfgang Pauli Strasse 10, 8093 Zurich, Switzerland.
Diabetologia. 2012 Sep;55(9):2407-16. doi: 10.1007/s00125-012-2605-2. Epub 2012 Jul 13.
AIMS/HYPOTHESIS: Non-invasive diagnostic tools specific for pancreatic beta cells will have a profound impact on our understanding of the pathophysiology of metabolic diseases such as diabetes. The objective of this study was to use molecular imaging probes specifically targeting beta cells on human samples and animal models using state-of-the-art imaging modalities (fluorescence and PET) with preclinical and clinical perspective.
We generated a monoclonal antibody, 8/9-mAb, targeting transmembrane protein 27 (TMEM27; a surface N-glycoprotein that is highly expressed on beta cells), compared its expression in human and mouse pancreas, and demonstrated beta cell-specific binding in both. In vivo imaging was performed in mice with subcutaneous insulinomas overexpressing the human TMEM27 gene, or transgenic mice with beta cell-specific hTMEM27 expression under the control of rat insulin promoter (RIP-hTMEM27-tg), using fluorescence and radioactively labelled antibody, followed by tissue ex vivo analysis and fluorescence microscopy.
Fluorescently labelled 8/9-mAb showed beta cell-specific staining on human and mouse pancreatic sections. Real-time PCR on islet cDNA indicated about tenfold higher expression of hTMEM27 in RIP-hTMEM27-tg mice than in humans. In vivo fluorescence and PET imaging in nude mice with insulinoma xenografts expressing hTMEM27 showed high 8/9-mAb uptake in tumours after 72 h. Antibody homing was also observed in beta cells of RIP-hTMEM27-tg mice by in vivo fluorescence imaging. Ex vivo analysis of intact pancreas and fluorescence microscopy in beta cells confirmed these findings.
CONCLUSIONS/INTERPRETATION: hTMEM27 constitutes an attractive target for in vivo visualisation of pancreatic beta cells. Studies in mouse insulinoma models and mice expressing hTMEM27 demonstrate the feasibility of beta cell-targeted in vivo imaging, which is attractive for preclinical investigations and holds potential in clinical diagnostics.
目的/假设:针对胰腺β细胞的非侵入性诊断工具将对我们理解代谢性疾病(如糖尿病)的病理生理学产生深远影响。本研究的目的是使用针对人类样本和动物模型中β细胞的分子成像探针,采用最先进的成像方式(荧光和 PET),从临床前和临床角度进行研究。
我们生成了一种针对跨膜蛋白 27(TMEM27;高度表达于β细胞的表面 N-糖蛋白)的单克隆抗体 8/9-mAb,比较了其在人和小鼠胰腺中的表达,并证明了在两者中均具有β细胞特异性结合。在皮下过表达人 TMEM27 基因的胰岛素瘤小鼠或在大鼠胰岛素启动子(RIP-hTMEM27-tg)控制下β细胞特异性表达 hTMEM27 的转基因小鼠中,进行了荧光和放射性标记抗体的体内成像,然后进行组织离体分析和荧光显微镜检查。
荧光标记的 8/9-mAb 在人胰腺和小鼠胰腺切片上显示出β细胞特异性染色。对胰岛 cDNA 的实时 PCR 分析表明,在 RIP-hTMEM27-tg 小鼠中 hTMEM27 的表达比在人类中高约 10 倍。在表达 hTMEM27 的胰岛素瘤异种移植裸鼠中进行的体内荧光和 PET 成像显示,在 72 小时后,8/9-mAb 在肿瘤中摄取量很高。通过体内荧光成像,也观察到 RIP-hTMEM27-tg 小鼠中 hTMEM27 的抗体归巢。对完整胰腺的离体分析和β细胞的荧光显微镜检查证实了这些发现。
结论/解释:hTMEM27 是胰腺β细胞体内可视化的有吸引力的靶标。在小鼠胰岛素瘤模型和表达 hTMEM27 的小鼠中的研究证明了β细胞靶向体内成像的可行性,这对于临床前研究具有吸引力,并具有在临床诊断中的潜力。